Literature DB >> 30393019

Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition.

Elodie M Varin1, Erin E Mulvihill1, Jacqueline L Beaudry1, Gemma Pujadas1, Shai Fuchs1, Jean-François Tanti2, Sofia Fazio2, Kirandeep Kaur1, Xiemin Cao1, Laurie L Baggio1, Dianne Matthews1, Jonathan E Campbell1, Daniel J Drucker3.   

Abstract

Dipeptidyl peptidase-4 (DPP-4) controls glucose homeostasis through enzymatic termination of incretin action. We report that plasma DPP-4 activity correlates with body weight and fat mass, but not glucose control, in mice. Genetic disruption of adipocyte Dpp4 expression reduced plasma DPP-4 activity in older mice but did not perturb incretin levels or glucose homeostasis. Knockdown of hepatocyte Dpp4 completely abrogated the obesity-associated increase in plasma DPP-4 activity, reduced liver cytokine expression, and partially attenuated inflammation in adipose tissue without changes in incretin levels or glucose homeostasis. In contrast, circulating levels of soluble DPP4 (sDPP4) were dissociated from inflammation in mice with endothelial-selective or global genetic inactivation of Dpp4. Remarkably, inhibition of DPP-4 enzymatic activity upregulated circulating levels of sDPP4 originating from endothelial or hematopoietic cells without inducing systemic or localized inflammation. Collectively, these findings reveal unexpected complexity in regulation of soluble versus enzymatic DPP-4 and control of inflammation and glucose homeostasis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adipocyte; diabetes; glucose; hepatocyte; incretin; inflammation; insulin resistance; obesity; soluble dipeptidylpeptidase 4

Mesh:

Substances:

Year:  2018        PMID: 30393019     DOI: 10.1016/j.cmet.2018.10.001

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  37 in total

Review 1.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

Review 2.  What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.

Authors:  Ahmed M Elmansi; Mohamed E Awad; Nada H Eisa; Dmitry Kondrikov; Khaled A Hussein; Alexandra Aguilar-Pérez; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Sadanand Fulzele; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Brian F Volkman; William D Hill
Journal:  Pharmacol Ther       Date:  2019-02-10       Impact factor: 12.310

3.  Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.

Authors:  Marcus Lettau; Michelle Dietz; Sarah Vollmers; Fred Armbrust; Christian Peters; Thi Mai Dang; Guranda Chitadze; Dieter Kabelitz; Ottmar Janssen
Journal:  Cell Mol Life Sci       Date:  2019-07-12       Impact factor: 9.261

Review 4.  Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy.

Authors:  Wenli Zhao; Le Zhou; Petr Novák; Xian Shi; Chuang Biao Lin; Xiao Zhu; Kai Yin
Journal:  J Diabetes Res       Date:  2022-06-09       Impact factor: 4.061

5.  GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue.

Authors:  Jonathan E Campbell; Jacqueline L Beaudry; Berit Svendsen; Laurie L Baggio; Andrew N Gordon; John R Ussher; Chi Kin Wong; Fiona M Gribble; David A D'Alessio; Frank Reimann; Daniel J Drucker
Journal:  Diabetes       Date:  2022-05-01       Impact factor: 9.337

6.  GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study.

Authors:  Helga Ellingsgaard; Eleonora Seelig; Katharina Timper; Michael Coslovsky; Line Soederlund; Mark P Lyngbaek; Nicolai J Wewer Albrechtsen; Arno Schmidt-Trucksäss; Henner Hanssen; Walter O Frey; Kristian Karstoft; Bente K Pedersen; Marianne Böni-Schnetzler; Marc Y Donath
Journal:  Diabetologia       Date:  2019-12-03       Impact factor: 10.122

Review 7.  Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation.

Authors:  Brent A McLean; Chi Kin Wong; Jonathan E Campbell; David J Hodson; Stefan Trapp; Daniel J Drucker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

8.  Targeting Soluble DPP-4 for Insulin Resistance: Origin Matters.

Authors:  Lale Ozcan; Devram S Ghorpade; Ira Tabas
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

Review 9.  Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.

Authors:  John R Ussher; Amanda A Greenwell; My-Anh Nguyen; Erin E Mulvihill
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

10.  Dipeptidyl peptidase IV inhibition delays developmental programming of obesity and metabolic disease in male offspring of obese mothers.

Authors:  Kim Ramil C Montaniel; Matthew Bucher; Elysse A Phillips; Cun Li; Elinor L Sullivan; Paul Kievit; Sandra Rugonyi; Peter W Nathanielsz; Alina Maloyan
Journal:  J Dev Orig Health Dis       Date:  2022-01-24       Impact factor: 3.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.